Subscribe to RSS
DOI: 10.1055/s-0033-1343485
No Significant Association between the Alpha-2A-Adrenergic Receptor Gene and Treatment Response in Combined or Inattentive Subtypes of Attention-Deficit Hyperactivity Disorder
Publication History
received 15 January 2013
revised 08 March 2013
accepted 29 March 2013
Publication Date:
03 July 2013 (online)
Abstract
Introduction:
Given the shortage of pharmacogenetic studies on treatment response according to subtype of attention-deficit hyperactivity disorder (ADHD), we investigated the associations between the MspI and DraI polymorphisms of the alpha-2 A-adrenergic receptor gene (ADRA2A) and treatment response to methylphenidate according to subtype of ADHD.
Methods:
We enrolled 115 medication-naïve children with ADHD into an open label 8-week trial of methylphenidate. The participants were genotyped and evaluated using the Clinical Global Impression (CGI), ADHD rating scale, and Continuous Performance Test (CPT) pre- and post-treatment.
Results:
There was no statistically significant association between the MspI or DraI genotypes and the relative frequency of CGI-improvement (CGI-I) 1 or 2 status among any of the groups (all types of ADHD, ADHD-C, or ADHD-I). However, among the children with ADHD-C, those subjects with the C/C genotype at the ADRA2A DraI polymorphism tended to have a CGI-I 1 or 2 status post-treatment (OR=4.45, p=0.045).
Discussion:
The results of this study do not support the association between the the MspI or DraI genotypes and treatment response to methylphenidate in ADHD. However, our results suggest that subtypes might influence pharmacogenetic results in ADHD.·
Key words
attention-deficit/hyperactivity disorder - ADRA2A - treatment response - subtype - methylphenidateSupporting information
- available online at http://www.thieme-connect.de/ejournals/toc/pharmaco
- Supporting information
-
References
- 1 Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237-248
- 2 Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44: 951-958
- 3 Amerian Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th, Text Revision ed. Washington, DC: Amerian Psychiatric Association; 2000
- 4 Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46: 1234-1242
- 5 Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35: 264-272
- 6 Arnsten AF. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 2006; 31: 2376-2383
- 7 Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53: 448-455
- 8 Greene CM, Bellgrove MA, Gill M et al. Noradrenergic genotype predicts lapses in sustained attention. Neuropsychologia 2009; 47: 591-594
- 9 Lario S, Calls J, Cases A et al. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 1997; 51: 129-130
- 10 Hoehe MR, Berrettini WH, Lentes KU. Dra I identifies a two allele DNA polymorphism in the human alpha 2-adrenergic receptor gene (ADRAR), using a 5.5 kb probe (p ADRAR). Nucleic Acids Res 1988; 16: 9070
- 11 Comings DE, Gade-Andavolu R, Gonzalez N et al. Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clinical genetics 1999; 55: 160-172
- 12 Comings DE, Gonzalez NS, Cheng Li SC et al. A “line item” approach to the identification of genes involved in polygenic behavioral disorders: the adrenergic alpha2A (ADRA2A) gene. Am J Med Genet B. Neuropsychiatr Genet 2003; 118B: 110-114
- 13 Roman T, Schmitz M, Polanczyk GV et al. Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? Am J Med Genet B. Neuropsychiatr Genet 2003; 120B: 116-120
- 14 Park L, Nigg JT, Waldman ID et al. Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol Psychiatry 2005; 10: 572-580
- 15 Cho SC, Kim JW, Kim BN et al. Possible association of the alpha-2A-adrenergic receptor gene with response time variability in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 957-963
- 16 Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Human Genet 2009; 126: 51-90
- 17 Polanczyk G, Zeni C, Genro JP et al. Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics 2005; 6: 225-234
- 18 Cheon KA, Cho DY, Koo MS et al. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiatry 2009; 65: 564-570
- 19 Polanczyk G, Zeni C, Genro JP et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64: 218-224
- 20 Contini V, Victor MM, Cerqueira CC et al. Adrenergic alpha2A receptor gene is not associated with methylphenidate response in adults with ADHD. Eur Arch Psychiatry Clin Neurosci 2011; 261: 205-211
- 21 Hong SB, Kim JW, Cho SC et al. Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?. J Child Adoles Psychopharmacol 2012; 22: 343-352
- 22 da Silva TL, Pianca TG, Roman T et al. Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type. J Neural Transm 2008; 115: 341-345
- 23 Willcutt EG, Pennington BF, DeFries JC. Etiology of inattention and hyperactivity/impulsivity in a community sample of twins with learning difficulties. J Abnorm Child psychol 2000; 28: 149-159
- 24 Kim YS, Cheon KA, Kim BN et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J 2004; 45: 81-89
- 25 Park JR KY, Park HJ. Korean educational developmental institute-Wechsler intelligence scale for children (KEDI-WISC). 2002;
- 26 So YK, Noh JS, Kim YS et al. The reliability and validity of Korean parent and teacher ADHD rating scale. J Korean Neuropsychiatr Assoc 2002; 41: 283-289
- 27 DuPaul GJ. Parent and teacher ratings of ADHD symptoms – Psychometric properties in a community-based sample. J Clin Child Psychol 1991; 20: 245-253
- 28 Cunningham CE, Siegel LS, Offord DR. A dose-response analysis of the effects of methylphenidate on the peer interactions and simulated classroom performance of ADD children with and without conduct problems. J Child Psychol Psychiatry 1991; 32: 439-452
- 29 National Institute of Mental Health . CGI, Clinical Global Impressions. Chevy Chase, Maryland: National Institute of Mental Health; 1970
- 30 Sung YS, Cho SC. The standardization of Korean CGI-I and CGI-S in children. In: Proceedings of Annual Meeting of Korean Neuropsychiatric Association. 1995
- 31 Greenberg LM, Waldman ID. Developmental normative data on the test of variables of attention (T.O.V.A.). J Child Psychol Psychiatry, Allied Disciplines 1993; 34: 1019-1030
- 32 Shin MS, Cho S, Chun SY et al. A study of the development and standardization of ADHD Diagnostic System. Korean J Child Adol Psychiatr 2000; 11: 91-99
- 33 Buitelaar JK, Kooij JJ, Ramos-Quiroga JA et al. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 554-560
- 34 Tamm L, Trello-Rishel K, Riggs P et al. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. J Subst Abuse Treat 2013; 44: 224-230